Clinical preliminary observation on image-guided brachytherapy for cervical cancer

龚　唯; 徐晓婷; 李　莉

doi:10.3969/j.issn.1007-3969.2015.11.011

您当前的位置：

首页 >

文章列表页 >

Clinical preliminary observation on image-guided brachytherapy for cervical cancer

更新时间：2025-12-31

- Clinical preliminary observation on image-guided brachytherapy for cervical cancer
- China Oncology Vol. 25, Issue 11, Pages: 906-910(2015)
- 作者机构：
  
  苏州大学附属第一医院放疗科,江苏,苏州,215006
- 作者简介：
- 基金信息：
- DOI：10.3969/j.issn.1007-3969.2015.11.011
  CLC：
- Published Online：01 February 2016，
  
  Published：01 February 2015
- 稿件说明：
移动端阅览
龚　唯,徐晓婷,李　莉,等. 影像引导宫颈癌三维腔内放疗的临床初步观察[J]. 中国癌症杂志, 2015, 25(11): 906-910.

龚　唯, 徐晓婷, 李　莉. Clinical preliminary observation on image-guided brachytherapy for cervical cancer[J]. China Oncology, 2015, 25(11): 906-910.
龚　唯,徐晓婷,李　莉,等. 影像引导宫颈癌三维腔内放疗的临床初步观察[J]. 中国癌症杂志, 2015, 25(11): 906-910. DOI： 10.3969/j.issn.1007-3969.2015.11.011.

龚　唯, 徐晓婷, 李　莉. Clinical preliminary observation on image-guided brachytherapy for cervical cancer[J]. China Oncology, 2015, 25(11): 906-910. DOI： 10.3969/j.issn.1007-3969.2015.11.011.

摘要

背景与目的：放射治疗是宫颈癌的主要治疗方法。通过分析苏州大学附属第一医院放疗科收治的31例初治宫颈癌患者三维腔内放疗的剂量体积直方图(dose-volume histogram，DVH)剂量分布和临床结果，观察影像引导宫颈癌三维后装放疗患者的近期疗效及放射反应。方法：选取2013年5月—2014年12月在苏州大学附属第一医院放疗科行根治性放疗的31例初治宫颈癌患者，FIGO期为Ⅱa~Ⅳ期。每例患者接受4~6次CT引导下的三维后装放疗，单次高危临床靶区(high risk-clinical target volume，HR-CTV)给予400~600 cGy处方剂量，31例患者共计153次施源器置入，采用

192

Ir高剂量率后装治疗机实施腔内放疗。分析内外照射的HRCTVD90、膀胱D2cc、乙状结肠D2cc、直肠D0.1cc和直肠D2cc，采用EQD2进行剂量计算。按照RTOG/EORTC放射反应评分标准和RECIST 1.1评价标准分析放射反应和近期疗效。结果：膀胱、直肠、乙状结肠均无3级及以上急性或慢性放射反应。2例患者发生后期直肠出血(2级)，经止血和灌肠等对症处理后症状改善。放疗后1~3个月完全缓解率(complete remission，CR)为93.55%(29/31)，1年局部控制率(local control rate，LCR)为93.55%(29/31)，1年无进展生存率(progression-free survival，PFS)为90.32%(28/31)。结论：CT引导的三维腔内放疗联合外照射治疗局部晚期宫颈癌，定位精确，靶区剂量充足，危及器官的受照剂量可见、可控、可信，提高了患者的治疗耐受性，避免了重度放射反应的发生，大大提高了患者治疗后的生活质量，值得推广应用。

Abstract

Background and purpose: The radiation therapy is the main treatment of cervical cancer. In order to investigate the efficacy and toxicity of the 3D image-guided brachytherapy for cervical cancer

we analyzed dose-volume histogram (DVH) dose distribution and clinical data from 31 cases of cervical cancer treated with three dimensional brachytherapy. Methods: From May. 2013 to Dec. 2014

31 cervical cancer cases with FIGO stage Ⅱa-Ⅳ received comprehensive treatmen

t in our department. High risk-clinical target volume (HR-CTV) was 400-600 cGy per fraction

and totally 4-6 fractions for each patient. A total of 152 times 3D-CT guided brachytherapy was performed with

192

Ir high-dose-rate afterloader. We calculated the doses with EQD2 and analyzed the data on HRCTV D90

bladder D2cc

sigmoid D2cc

rectum D0.1cc and rectum D2cc of both the external-beam radiotherapy and CT-guided brachytherapy. The efficacy and toxicity were evaluated by RTOG/EORTC and RECIST (version 1.1) guideline. Results: There was no third degree reaction occurring on bladder

rectum or sigmoid. Two patients developed second degree chronic rectal bleeding 3 months after the completion of radiotherapy which were well controlled by medications. The tumor complete remission rate (CR) was 93.55% (29/31) 1-3 months after the treatment. Local control rate (LCR) rate was 93.55% (29/31) one year after the treatment

whereas disease-free survival rate (DFS) was 90.32% (28/31). Conclusion: The 3D CT-guided brachytherapy combined with external radiation for locally advanced cervical cancer showed positioning accuracy with an adequate dose distribution to the target area. The treatment made the OR dose visible

controllable and credible. It improved the treatment of patients with increased tolerance and avoided the severe radiation reactions. Thus

the combination therapy may greatly improve the quality of life for patients

and ought to be promoted.

关键词

Keywords

references

Views

2365

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Mechanism of immune escape mediated by T cell depletion induced by TOX signaling pathway in cervical cancer microenvironment

Effectiveness and safety analysis of camrelizumab combined with chemotherapy and targeted therapy in patients with recurrent, metastatic, and treatment-naive advanced cervical cancer: a retrospective cohort study

Effects of TMCO1 on proliferation and migration of cervical cancer cells

Progress in treatment of gynecological cancer in 2023

Metastasis patterns and survival analysis of 572 patients with metastatic cervical cancer: a hospital-based real world study

Related Author

Yuxi TANG

Chengfang XIE

Yan XU

Dan XIE

Guxiang ZHANG

Dan LIU

Laifang ZHU

Sumei FAN

Related Institution

Department of Obstetrics and Gynecology, The Fourth Hospital of Changsha (Integrated Traditional Chinese and Western Medicine Hospital of Changsha, Changsha Hospital of Hunan Normal University)

Department of Diagnostic Radiology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University

Department of Surgical Oncology, Minhang Branch, Fudan University Shanghai Cancer Center

Department of Pharmacy, Minhang Branch, Fudan University Shanghai Cancer Center

Department of Diagnostic Radiology, Minhang Branch, Fudan University Shanghai Cancer Center

AI问答

⁰